Technology News and Research

RSS

SpectraCell Laboratories introduces apolipoprotein E genotyping

Effective immediately, SpectraCell Laboratories now offers apolipoprotein E genotyping. This test determines a person's genetic risk for heart disease associated with the commonly studied gene called apoE, which is involved in the metabolism of cholesterol and triglycerides (fats in the blood).

22 Apr 2010

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cancer, ASG-5ME was found to have potent and long lasting antitumor activity. The findings were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

22 Apr 2010

Aspen Dental donates $2,300 to Oral Cancer Foundation for cancer detection and treatment

Aspen Dental announced today that the company will donate $2,300 to the Oral Cancer Foundation as part of its commitment to oral cancer detection and treatment. The amount represents a $5 donation for every Vizilite Plus screening conducted at Aspen Dental offices during Oral, Head, and Neck Cancer Awareness Week (April 12-18, 2010).

22 Apr 2010

Affymetrix reports first-quarter total revenue of $80.2M

Affymetrix, Inc., today reported its operating results for the first quarter of 2010. Total revenue for the quarter was $80.2 million, as compared to total revenue of $78.6 million in the first quarter of 2009.

22 Apr 2010

LIJ Medical Center to acquire TrueBeam system for cancer treatment

In a promising development for cancer patients in the New York metropolitan area, the Long Island Jewish (LIJ) Medical Center Department of Radiation Medicine announced today that it will acquire an innovative new system called TrueBeam that offers a radically different approach to treating cancer with image-guided radiotherapy.

22 Apr 2010

Cook Medical enrolls first patient in Formula PTX Balloon Expandable Renal Stent trial

Angiotech Pharmaceuticals, Inc. today announced Cook Medical, a license holder of Angiotech's paclitaxel technology, has enrolled the first patient in its landmark Formula PTX clinical trial. The trial is the first of its kind to evaluate the safety and effectiveness of a paclitaxel-eluting stent to treat renal artery disease, the narrowing of the arteries that supply blood to the kidneys.

22 Apr 2010

Medtronic acquires Invatec

Moving to expand its product offering, Medtronic, Inc., announced today that it has completed the acquisition of Invatec, a developer of innovative medical technologies for the interventional treatment of cardiovascular disease.

22 Apr 2010

Health record push lacks FDA oversight, risks safety problems

The Huffington Post Investigative Fund: "As federal officials encourage the rapid expansion of electronic medical records to help doctors improve care and cut costs, they lack a reliable and systematic method for tracking the safety of these products, agency data and audits show. Instead, the Food and Drug Administration depends on a spotty warning system that can take a year to flag serious computer malfunctions and other software glitches.

22 Apr 2010

Online Wiki offers information, comfort and community for families facing autism transition

Among the many challenges families caring for individuals with autism spectrum disorders face, perhaps the most difficult of all arrive "when the school bus stops." When a child with autism ages out of systems and supports designed for those up to ages 18-21, families face the daunting challenge of finding new resources and creating new communities for their children. Unfortunately, finding necessary services and supports can be very difficult.

22 Apr 2010

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

Labopharm Inc. today introduced INTELLITAB(TM), the brand name for its proprietary abuse and misuse-deterrent technology platform. The INTELLITAB(TM) platform, which can deliver one or more therapeutic drugs in combination over periods of up to 24 hours, has the potential to provide a patient with a controlled release medication while minimizing the risk of intentional abuse or accidental misuse.

21 Apr 2010

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, today announced it has completed a $39.6 million Series A financing led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures. Also participating in the round is Advanced Technology Ventures.

21 Apr 2010

Rheonix announces completion of $12.6 million Series A financing

Rheonix, Inc. today announced the completion of a $12.6 million Series A financing to continue development of the Rheonix CARD™ (Chemistry And Reagent Device) system. This powerful, analytic platform for the life-science industry vertically integrates all the functions of traditional molecular diagnostic instrumentation into a single system to achieve unprecedented raw sample preparation, molecular amplification and multiplex analysis.

21 Apr 2010

Health Grades' ratings and advisory revenue for first-quarter up 20%

Health Grades, Inc., the leading independent healthcare ratings company, today reported financial results for the first quarter ended March 31, 2010.

21 Apr 2010

BIO-key International, Healthcare-ID to present biometric identity solutions at 56th CBBS Annual Meeting

BIO-key International, Inc., a leader in finger-based biometric identification solutions, today announced that BIO-key and its partner, Healthcare-ID, a leader in automated donor management solutions, will jointly participate at the 56th Annual Meeting of the California Blood Bank Society in BOOTH #123.

21 Apr 2010

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.

21 Apr 2010

IP Advocate founder settles long-standing legal battle with UGARF

In a move that positions IP Advocate for its next chapter as a champion of research translation, founder Dr. Renee Kaswan today announced that she has settled her long-standing legal battle with the University of Georgia Research Foundation.

21 Apr 2010

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced it has received important commitments from two leading research laboratories in India for clinical validation testing for malaria and tuberculosis (TB) detection and diagnosis.

21 Apr 2010

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia's subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC. The data demonstrates the ability of the Company's HyACT tumour targeting technology to dramatically enhance the killing of cancer stem cells. These cells are highly resistant to treatment with chemotherapeutic drugs and are believed to be responsible for treatment failure and disease recurrence.

21 Apr 2010

Study assesses use of eMedonline to help manage patients' compliance with Gleevec

A clinical study underway at Rex Cancer Center of Wakefield will evaluate the use of telemonitoring in managing administration of Gleevec, a drug developed and manufactured by Novartis to treat chronic myeloid leukemia.

21 Apr 2010

French Ministry of Research grants French R&D tax credit accreditation to Cyprotex

Cyprotex, the drug discovery technology and information company, is pleased to announce that it has received French research tax credit approval for years 2009 through to 2011.

21 Apr 2010

Technology News and Research

SpectraCell Laboratories introduces apolipoprotein E genotyping

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

Aspen Dental donates $2,300 to Oral Cancer Foundation for cancer detection and treatment

Affymetrix reports first-quarter total revenue of $80.2M

LIJ Medical Center to acquire TrueBeam system for cancer treatment

Cook Medical enrolls first patient in Formula PTX Balloon Expandable Renal Stent trial

Medtronic acquires Invatec

Health record push lacks FDA oversight, risks safety problems

Online Wiki offers information, comfort and community for families facing autism transition

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Rheonix announces completion of $12.6 million Series A financing

Health Grades' ratings and advisory revenue for first-quarter up 20%

BIO-key International, Healthcare-ID to present biometric identity solutions at 56th CBBS Annual Meeting

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

IP Advocate founder settles long-standing legal battle with UGARF

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Study assesses use of eMedonline to help manage patients' compliance with Gleevec

French Ministry of Research grants French R&D tax credit accreditation to Cyprotex

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News